admin – Page 2404 – Get News Story

Best MedSpa Marketing Company in 2025: iHealth Marketing Sets the Standard for Growth in the Aesthetics Industry

iHealth Marketing has been named the best medspa marketing company in 2025, offering tailored digital strategies to help medical spas attract more clients, boost visibility, and maximize revenue. Led by Business Development Specialist James Vale, the agency delivers results-driven services including SEO, paid ads, social media, web design, and content marketing for medspas nationwide.

In a year where the U.S. medspa industry is projected to surpass $6 billion, iHealth Marketing is redefining what it means to be the best medspa marketing company in 2025. Known for its healthcare-specific expertise, the agency is helping medical spas nationwide capture market share with advanced digital marketing strategies that drive measurable growth.

Rather than offering one-size-fits-all marketing, iHealth Marketing builds fully customized campaigns for each medspa client — integrating local SEO, paid advertising, social media engagement, and high-converting web design into a cohesive growth plan.

“Too many medspa owners waste money on generic marketing that doesn’t connect with their ideal audience,” said James Vale, Business Development Specialist at iHealth Marketing. “Our approach focuses on attracting the right clients, at the right time, with messaging that converts. That’s what makes us the best medspa marketing company in 2025.”

Raising the Bar for MedSpa Marketing

iHealth Marketing’s success stems from a mix of industry specialization and data-driven execution. Services include:

Search Engine Optimization (SEO) to capture top local rankings for high-value treatments like Botox, fillers, and laser services.
Precision Paid Ads across Google, Bing, Facebook, and Instagram to generate consistent client inquiries.
Conversion-Optimized Websites that turn clicks into booked appointments.
Brand-Building Content that strengthens trust and positions medspas as local leaders.
Performance Tracking with transparent reporting and ongoing strategy adjustments.

Why 2025 Demands a Specialized Partner

The aesthetics market is growing fast, but so is competition. According to industry data, the average medspa now competes with more than 25 providers within a 10-mile radius. iHealth Marketing’s industry-specific tactics help medspas stand out in crowded markets and keep their appointment schedules full.

“We know the nuances of medspa marketing — from compliance considerations to seasonal promotions,” Vale added. “That expertise translates into campaigns that work harder and deliver stronger ROI.”

Invitation to MedSpa Owners

iHealth Marketing is currently offering complimentary marketing assessments for medspa owners who want to evaluate their current efforts and identify untapped growth opportunities.

About iHealth Marketing

iHealth Marketing is a results-driven medspa marketing company specializing in the growth of medical spas and healthcare practices nationwide. The agency offers SEO, PPC, social media, web design, and content marketing, all tailored to the aesthetics industry.

Learn more at ihealthmarketing.com/medical-spa-marketing-company/

Media Contact
Company Name: iHealthMarketing
Contact Person: James Vale
Email: Send Email
Phone: (866) 679-1001
Address:10080 Carroll Canyon Road
City: San Diego
State: California
Country: United States
Website: https://ihealthmarketing.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Best MedSpa Marketing Company in 2025: iHealth Marketing Sets the Standard for Growth in the Aesthetics Industry

Manhattan In-Home Memory Care Lifts Cognition with Touching Hearts at Home NYC This Alzheimer’s Day

Caregiver supports senior during cognitive activity—Touching Hearts at Home NYC’s dignity-centered memory care in action.

Touching Hearts at Home NYC caregivers reduce fall risks by 30% with home safety plans and memory walks giving confidence to Manhattan seniors during Alzheimer’s Month

NEW YORK, NY – August 14, 2025 – According to the Alzheimer’s Association 2025 Report, dementia impacts 1 in 8 New York seniors and increases fall risks fivefold. As World Alzheimer’s Day approaches this September, Touching Hearts at Home NYC answers this need with its award-winning Manhattan In-Home Memory Care, blending research-supported safety strategies with personalized companionship to preserve dignity where seniors feel most secure: within their own homes.

For older New Yorkers, falls represent more than accidents—they threaten cherished independence. Seniors with dementia account for 40% of fall-related hospitalizations according to CDC data. Touching Hearts at Home NYC addresses these concerns through thoughtful, individualized support. Caregivers create safer living spaces by replacing hazardous rugs with non-slip alternatives, installing motion-activated lighting for nighttime navigation, and decluttering hallways to prevent disorientation-related falls.

Safety extends outdoors during memory walks in Central Park, where benches serve as gentle balance-practice stations and railings support strength-building steps. These personalized approaches align with World Health Organization findings showing 30% fewer fall injuries when honoring each senior’s mobility needs—whether assisting with grocery carrying or supporting strolls to neighborhood cafes.

Adair W., an Upper West Side client, describes her husband’s experience: “After his dementia diagnosis, we stopped visiting our favorite bakery. His caregiver noticed how much he missed those walks and gradually reintroduced them—starting with short steps to the lobby, then building to full trips. Now he enjoys morning bagels again. That patience gave us back simple joys we thought were lost.”

This commitment to sustaining identity defines Touching Hearts at Home NYC’s memory care in NYC. Caregivers integrate strength-building into meaningful routines: converting coffee preparation into gentle arm exercises, transforming closet organization into standing/sitting practice, or turning puzzle-solving into cognitive engagement. These activities maintain physical vitality while reducing isolation—key factors in slowing memory decline.

“Behaviors are expressions of need we humbly strive to understand,” explains Craig Sendach, owner of Touching Hearts at Home NYC. “When a client resists bathing, we might introduce warm lavender towels. If they pace anxiously, we initiate seated chair exercises. It’s about responding with creativity—never imposing rigid solutions.”

The Alzheimer’s Association reports that 74% of family caregivers experience health-impacting exhaustion. During World Alzheimer’s Month, Touching Hearts at Home NYC provides restorative respite so families reclaim moments of connection. As one daughter shared, “Seeing Mom laugh while arranging flowers with her caregiver—instead of stressing over forgotten steps—finally let me breathe. That peace of mind is a priceless gift.”

“Aging with Dementia in Manhattan means protecting the rhythms that make life meaningful,” Sendach emphasizes. “We safeguard independence by adapting to treasured routines: morning news discussions over tea, walks to local markets, or arranging family photos. Our care isn’t about taking over—it’s about walking alongside seniors as they lead their own stories.”

As World Alzheimer’s Day approaches this September, Touching Hearts at Home NYC enables seniors to participate in the 2025 Walk to End Alzheimer’s through supported memory walks in Central Park—where caregivers provide balance support and community connection while prioritizing fall safety.

To learn more about how Manhattan In-Home Memory Care integrates fall prevention strategies with personalized cognitive support, please visit https://www.touchinghearts.com/nyc/

About Touching Hearts at Home NYC Area

Located in NYC, Touching Hearts at Home NYC is part of the Touching Hearts at Home network, providing in-home care to aging adults, seniors, and individuals living with medical conditions and disabilities at rates considerably more affordable than care outside the home. The agency is known for Non-Medical Home Care, Companionship, and Homemaker services in New York City’s Manhattan, Brooklyn, Westchester, Queens, and Rockland areas. Its focus is on providing person-centered care to help those in need remain in their home, maintain the lifestyle they choose, and feel confident they will be treated with the respect and kindness they deserve.

Media Contact
Company Name: Touching Hearts at Home NYC Area
Contact Person: Craig Sendach
Email: Send Email
Phone: 2122016139
Address:733 3rd Avenue Floor 16
City: New York
State: NY
Country: United States
Website: https://www.touchinghearts.com/nyc/

Posada Del Sol Announces New Management and Exciting Upgrades to 55+ Mobile Home & RV Community in Harlingen, TX

Posada Del Sol, a 55+ mobile home and RV resort in Harlingen, Texas, announces new management and exciting upgrades, enhancing amenities, infrastructure, and resident experience for a vibrant senior community.

Posada Del Sol, a beloved 55+ mobile home and RV resort community in Harlingen, Texas, is proud to announce a new chapter in its journey. Now under fresh management, the community is undergoing exciting upgrades and enhancements designed to provide an improved living experience for current and future residents.

Known for its quiet charm, friendly neighbours, and desirable location in the Rio Grande Valley, Posada Del Sol has long been a destination for Winter Texans and retirees looking for a peaceful, well-connected lifestyle. With this transition to new leadership, the resort is reaffirming its commitment to offering high-quality, affordable senior living within a vibrant and caring community.

Fresh Vision, Better Living

The new management team brings renewed energy, deep industry expertise, and a clear focus on enhancing the infrastructure, amenities, and resident experience. Already underway are improvements to the park’s facilities, including upgrades to communal spaces such as the pool, hot tub, and recreation hall. Enhanced landscaping, improved maintenance schedules, and long-term infrastructure planning are also part of the vision to make Posada Del Sol the top choice for active adults 55+ in the region.

“We’re excited about this new chapter at Posada Del Sol,” said Erika Martinez, Community Manager. “Our goal is to create a space where residents feel proud to live, where they’re supported, and where they can truly enjoy their golden years. With every improvement, we are working to ensure safety, comfort, and connection for our residents.”

Why It Matters

This change in management addresses prior concerns about upkeep and responsiveness, providing residents with reassurance that their needs are a top priority. The proactive upgrades serve not only to enhance property value and aesthetics but also to build stronger trust within the community. These improvements are vital to attracting new residents and retaining the warmth and sense of belonging that have always defined Posada Del Sol.

The updates are also timely, as more seniors seek safe, affordable housing options in friendly and sunny locations like Harlingen. Posada Del Sol offers just that—with spacious lots, modern amenities, and a calendar full of social opportunities for neighbors to come together and build lasting friendships.

Join the Posada Del Sol Community

For prospective residents considering their next chapter, Posada Del Sol offers the perfect blend of tranquillity, connection, and convenience. Whether you’re staying seasonally or looking to put down roots in a thriving 55+ community, you’ll find that Posada Del Sol stands out for its thoughtful design, responsive team, and ongoing investment in its people and place.

To follow the progress and learn more about upcoming events and upgrades, connect with Posada Del Sol on Facebook or visit hometowncommunities.com. You can also explore the location via Google Maps.

About Posada Del Sol

Posada Del Sol is a peaceful and welcoming 55+ mobile home and RV resort community located in Harlingen, Texas. The park offers spacious lots, a full range of amenities including a pool, hot tub, and recreation hall, and a friendly, neighbourly atmosphere perfect for Winter Texans and long-term residents alike. Now under new management, Posada Del Sol is focused on creating a vibrant and well-maintained living environment for all.

Media Contact
Company Name: Posada Del Sol MHP LLC
Contact Person: Erika Martinez
Email: Send Email
Phone: 956-420-4287
Address:28513 S Palm Court Dr
City: Harlingen
Country: United States
Website: hometowncommunties.com

Cooking Guild’s Kaiju Knife Series Enters Phase 3 After Record Sell-Outs Across U.S.

“The Cooking Guild’s Kaiju Series Knives”

The Cooking Guild launches Phase 3 of its acclaimed Kaiju Knife Series after record sell-outs in the US. Featuring new additions like the 10” Serrated Slicer, 4-piece Steak Knife Set, Paring Knife, and Modular Knife Block, each blade is hand-forged from premium Japanese steel for unmatched precision, durability, and performance.

DELAWARE, USA – Aug 14, 2025 – The Cooking Guild has rolled out Phase 3 of its Kaiju Knife Series, following consecutive sellouts of earlier releases in both U.S. and European markets. The new phase includes three handcrafted knives and a modular knife block, forming what the company calls its most complete product drop yet.

The expansion follows a strong run of rapid sell-throughs. Phase 1 sold out in under six weeks, while Phase 2 inventory was gone in less than four. The company reports that demand continues to exceed supply, with waitlists forming in multiple countries and thousands of customers signing up for early access.

“Our plan from the beginning was to build the Kaiju Series in stages,” said Curtis Wright, CEO and founder of The Cooking Guild. “Each release gave us the opportunity to grow the collection while staying in tune with customer feedback. When Phase 2 sold out in just 26 days, it became clear we needed to move faster on completing the lineup.”

Phase 3 introduces a 10-inch serrated slicer, a 5-inch paring knife, and a four-piece steak knife set. It also debuts the Kaiju Knife Block, a modular storage solution designed to house the full collection, including previously released chef, bunka, utility, and cleaver knives.

Wright said the new knife block responds to an increasing number of customer requests for dedicated storage. “People weren’t just asking for more blades,” he said. “They wanted a way to store and display them, something that matched the look and feel of the knives themselves. That’s what led us to develop the Kaiju Block.”

The knives in the series are forged from high-carbon Japanese steels, such as AUS-8 and SLD San Mai. Each features full-tang construction and water-resistant pakkawood handles. The blades are hand-forged and sharpened individually, a process the company says has extended production timelines but helped maintain product quality and customer interest.

Reports show over 1,000 five-star reviews and more than 500,000 knives delivered to households in the U.S. since the Kaiju Series launched. Preorders for Phase 3 began this week and will be released in limited batches due to manufacturing capacity.

The phased rollout has allowed The Cooking Guild to manage production while responding to shifting market demand. Each new release has expanded the collection’s range and driven continued engagement from both professional chefs and home cooking enthusiasts.

According to Wright, the phase-based model will continue to shape future product development. While Phase 3 brings the Kaiju line closer to completion, he noted that additional tools and accessories may be added over time.

The Cooking Guild operates with a direct-to-consumer model, handling its own design, forging, and fulfillment. The company emphasizes traditional techniques and small-batch production and has developed a customer base that includes culinary professionals and collectors who value craftsmanship over mass production.

About The Cooking Guild

The Cooking Guild is a Delaware-based knife manufacturer that produces hand-forged kitchen tools using traditional methods. The company specializes in high-carbon Japanese steels and full-tang construction, serving both professional and home chefs. Its limited-release strategy has helped build a dedicated following focused on performance and craftsmanship.

About the Kaiju Series

Launched in early 2024, the Kaiju Series is The Cooking Guild’s signature knife collection. Known for its durability and precision, the series has seen successive sellouts across global markets. Each knife combines traditional forging techniques with modern design to meet the needs of serious cooks.

Contact:

Email: pr@thecookingguild.com

Website: https://www.thecookingguild.com

Media Contact
Company Name: The Cooking Guild
Contact Person: Curtis Wright
Email: Send Email
Address:838 Walker Rd
City: Dover
State: Delaware
Country: United States
Website: thecookingguild.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cooking Guild’s Kaiju Knife Series Enters Phase 3 After Record Sell-Outs Across U.S.

Marginal Zone Lymphoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Marginal Zone Lymphoma pipeline constitutes 50+ key companies continuously working towards developing 50+ Marginal Zone Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Marginal Zone Lymphoma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Marginal Zone Lymphoma Market.

The Marginal Zone Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Marginal Zone Lymphoma Pipeline Report:

Companies across the globe are diligently working toward developing novel Marginal Zone Lymphoma treatment therapies with a considerable amount of success over the years.
Marginal Zone Lymphoma companies working in the treatment market are Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others, are developing therapies for the Marginal Zone Lymphoma treatment

Emerging Marginal Zone Lymphoma therapies in the different phases of clinical trials are- AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others are expected to have a significant impact on the Marginal Zone Lymphoma market in the coming years.
In August 2025, The US FDA has granted priority review to the supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel; Breyanzi), a CD19-targeted CAR T-cell therapy, for treating marginal zone lymphoma (MZL).
In August 2025, The FDA has accepted Bristol Myers Squibb’s supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel, Breyanzi), an autologous CD19-directed CAR T-cell therapy, for marginal zone lymphoma (MZL) with priority review. The Prescription Drug User Fee Act (PDUFA) target date is December 5, 2025. This sBLA is being evaluated for adults with relapsed/refractory (R/R) MZL who have undergone two or more prior systemic therapies and is supported by data from the Phase 2 TRANSCEND FL trial (NCT04245839).
In June 2025, A poster presentation at the ICML 2025 Congress highlighted the potential of combining rituximab and ibrutinib to treat marginal zone lymphoma (MZL). Currently, no standard frontline therapies exist for MZL patients. Previous studies have shown that BTK inhibitors offer a favorable risk-benefit profile for relapsed MZL across subtypes, including splenic (SMZL) and nodal (NMZL) forms. The phase II IELSG47/MALIBU trial evaluated the efficacy and safety of the rituximab and ibrutinib combination in treating MZL.
In February 2025, Bristol Myers Squibb (NYSE: BMY) announced that the Phase 2 TRANSCEND FL trial evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma achieved its primary endpoint in the marginal zone lymphoma (MZL) cohort. The results indicated that Breyanzi delivered a statistically significant and clinically meaningful overall response rate (ORR) in these patients.
In January 2025, Verismo Therapeutics, a clinical-stage CAR T company specializing in KIR-CAR platform technology, announced the dosing of the first patient in its CELESTIAL-301 Phase 1 clinical trial. The infusion took place at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado. The CELESTIAL-301 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of SynKIR™-310 in patients with relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL). This Phase 1 multicenter trial is enrolling patients who have previously undergone CAR T therapy but relapsed or became refractory, as well as those who have never received CAR T therapy.
In August 2024, The UK National Institute for Health and Care Excellence (NICE) has endorsed BeiGene’s Zanubrutinib (Brukinsa) for treating marginal zone lymphoma (MZL), a form of blood cancer, within the National Health Service (NHS). This approval introduces a new treatment option for patients in England, with the potential to slow cancer progression and reduce the need for additional chemotherapy.
In May 2024, ADC Therapeutics SA (NYSE: ADCT) has disclosed that preliminary findings from an investigator-launched Phase 2 clinical study assessing ZYNLONTA® (loncastuximab tesirine-lpyl) revealed a significant response rate among patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).
In April 2024, Verismo Therapeutics, a clinical-stage CAR T company pioneering the innovative KIR-CAR platform technology, has announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its Phase 1 clinical trial of SynKIR™-310. This trial aims to evaluate the efficacy of SynKIR™-310 in treating relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), which includes Diffuse Large B Cell lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL).
In March 2024, InnoCare Pharma has obtained approval for an investigational new drug application to commence a clinical study evaluating ICP-248 combined with orelabrutinib in China for the treatment of lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Marginal Zone Lymphoma Overview

Marginal Zone Lymphoma is a slow-growing type of non-Hodgkin lymphoma that originates from B-cells in the marginal zone of lymphoid tissues. It commonly affects the spleen, lymph nodes, or mucosa-associated lymphoid tissue (MALT). MZL often presents with painless swelling and may be linked to chronic infections or autoimmune disorders. Treatment varies based on the subtype and disease stage, ranging from watchful waiting to chemotherapy or targeted therapies.

Get a Free Sample PDF Report to know more about Marginal Zone Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/marginal-zone-lymphoma-pipeline-insight

Emerging Marginal Zone Lymphoma Drugs Under Different Phases of Clinical Development Include:

AS-1763: Carna Biosciences
Amdizalisib (HMPL689): Hutchmed
Parsaclisib (IBI376): Incyte/Innovent
Tafasitamab: MorphoSys/Incyte
Zanubrutinib: Beigene
Orelabrutinib: InnoCare Pharma
Tafasitamab: Incyte Corporation
MIL62: Beijing Mabworks Biotech Co.
Zandelisib: MEI Pharma, Inc./Kyowa Kirin
Loncastuximab: ADC Therapeutics
LOXO-305: Loxo Oncology
ADI-001: Adicet Bio
CDX-1140: Celldex Therapeutics Inc

Marginal Zone Lymphoma Route of Administration

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Marginal Zone Lymphoma Molecule Type

Marginal Zone Lymphoma Products have been categorized under various Molecule types, such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Marginal Zone Lymphoma Pipeline Therapeutics Assessment

Marginal Zone Lymphoma Assessment by Product Type
Marginal Zone Lymphoma By Stage and Product Type
Marginal Zone Lymphoma Assessment by Route of Administration
Marginal Zone Lymphoma By Stage and Route of Administration
Marginal Zone Lymphoma Assessment by Molecule Type
Marginal Zone Lymphoma by Stage and Molecule Type

DelveInsight’s Marginal Zone Lymphoma Report covers around 50+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Marginal Zone Lymphoma product details are provided in the report. Download the Marginal Zone Lymphoma pipeline report to learn more about the emerging Marginal Zone Lymphoma therapies

Some of the key companies in the Marginal Zone Lymphoma Therapeutics Market include:

Key companies developing therapies for Marginal Zone Lymphoma are – Incyte Corporation, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Incyte Corporation, Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc, Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, and others.

Marginal Zone Lymphoma Pipeline Analysis:

The Marginal Zone Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
Marginal Zone Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Marginal Zone Lymphoma drugs and therapies

Marginal Zone Lymphoma Pipeline Market Drivers

Increasing Prevalence, increased research and development are some of the important factors that are fueling the Marginal Zone Lymphoma Market.

Marginal Zone Lymphoma Pipeline Market Barriers

However, therapies with moderately good patient outcomes, long treatment course and other factors are creating obstacles in the Marginal Zone Lymphoma Market growth.

Scope of Marginal Zone Lymphoma Pipeline Drug Insight

Coverage: Global
Key Marginal Zone Lymphoma Companies: Carna Biosciences, Hutchmed, Incyte, Innovent, MorphoSys, Beigene, InnoCare Pharma, Beijing Mabworks Biotech Co., MEI Pharma, Inc., Kyowa Kirin, ADC Therapeutics, Loxo Oncology, Adicet Bio, Celldex Therapeutics Inc, and others
Key Marginal Zone Lymphoma Therapies: AS-1763, Amdizalisib (HMPL689), Parsaclisib (IBI376), Tafasitamab, Zanubrutinib, Orelabrutinib, Tafasitamab, MIL62, Zandelisib, Loncastuximab, LOXO-305, ADI-001, CDX-1140, and others
Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers

Request for Sample PDF Report for Marginal Zone Lymphoma Pipeline Assessment and clinical trials

Table of Contents

1. Marginal Zone Lymphoma Report Introduction

2. Marginal Zone Lymphoma Executive Summary

3. Marginal Zone Lymphoma Overview

4. Marginal Zone Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Marginal Zone Lymphoma Pipeline Therapeutics

6. Marginal Zone Lymphoma Late Stage Products (Phase II/III)

7. Marginal Zone Lymphoma Mid Stage Products (Phase II)

8. Marginal Zone Lymphoma Early Stage Products (Phase I)

9. Marginal Zone Lymphoma Preclinical Stage Products

10. Marginal Zone Lymphoma Therapeutics Assessment

11. Marginal Zone Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Marginal Zone Lymphoma Key Companies

14. Marginal Zone Lymphoma Key Products

15. Marginal Zone Lymphoma Unmet Needs

16 . Marginal Zone Lymphoma Market Drivers and Barriers

17. Marginal Zone Lymphoma Future Perspectives and Conclusion

18. Marginal Zone Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Marginal Zone Lymphoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys

Graves Disease Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, Hoffmann-La Roche

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Graves Disease pipeline constitutes 8+ key companies continuously working towards developing 10+ Graves Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Graves Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Disease Market.

The Graves Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Graves Disease Pipeline Report:

Companies across the globe are diligently working toward developing novel Graves Disease treatment therapies with a considerable amount of success over the years.
Graves Disease companies working in the treatment market are TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others, are developing therapies for the Graves Disease treatment

Emerging Graves Disease therapies in the different phases of clinical trials are- Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others are expected to have a significant impact on the Graves Disease market in the coming years.
In May 2025, Amgen has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved TEPEZZA® (teprotumumab) for marketing, making it the first authorized treatment specifically indicated for adult patients with moderate-to-severe Thyroid Eye Disease (TED).
In May 2025, Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to advancing and commercializing potentially best-in-class therapies for serious and rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to veligrotug (“veli”), its lead anti-IGF-1R drug candidate for the treatment of thyroid eye disease (TED).
In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company developing oral therapies for thyroid eye disease (TED), has announced topline efficacy and safety results from the Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company’s lead oral small molecule candidate taken twice daily, targets the well-established IGF-1R pathway. It has demonstrated a favorable safety profile, having been tested in over 900 patients across 15 clinical trials for various conditions.
In December 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to developing potentially best-in-class therapies for serious and rare conditions, has announced positive topline results from its Phase 3 THRIVE-2 clinical trial. The study evaluated veligrotug (veli), an intravenously administered anti-IGF-1R antibody, in patients with chronic thyroid eye disease (TED)—an autoimmune disorder marked by inflammation, tissue expansion, and damage around the eyes.

Graves Disease Overview

Graves’ disease is an autoimmune disorder that causes overactivity of the thyroid gland (hyperthyroidism). It leads to symptoms like weight loss, rapid heartbeat, and anxiety. The immune system mistakenly attacks the thyroid, causing it to produce excess hormones. Treatment includes medications, radioactive iodine, or surgery.

Get a Free Sample PDF Report to know more about Graves Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/graves-disease-pipeline-insight

Emerging Graves Disease Drugs Under Different Phases of Clinical Development Include:

Research Program: TSHR Septerna
Research Program: Cyclopeptides advanceCOR
Research Program: EVOQ Therapeutics
WP-1302: Worg Pharmaceuticals
K1-70: AV7 Limited
CFZ533: Novartis Pharmaceuticals
Batoclimab: Immunovant Sciences GmbH

Graves Disease Route of Administration

Graves Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Graves Disease Molecule Type

Graves Disease Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Graves Disease Pipeline Therapeutics Assessment

Graves Disease Assessment by Product Type
Graves Disease By Stage and Product Type
Graves Disease Assessment by Route of Administration
Graves Disease By Stage and Route of Administration
Graves Disease Assessment by Molecule Type
Graves Disease by Stage and Molecule Type

DelveInsight’s Graves Disease Report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Graves Disease product details are provided in the report. Download the Graves Disease pipeline report to learn more about the emerging Graves Disease therapies

Some of the key companies in the Graves Disease Therapeutics Market include:

Key companies developing therapies for Graves Disease are – Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific Inc., Institute of Isotopes Co. Ltd., bioMerieux SA, Horizon Therapeutics Ireland DAC, and others.

Graves Disease Pipeline Analysis:

The Graves Disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Graves Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves Disease Treatment.
Graves Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Graves Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves Disease market.

Download Sample PDF Report to know more about Graves Disease drugs and therapies

Graves Disease Pipeline Market Drivers

Increasing the prevalence of Graves Disease, increased public awareness about the treatment of Graves’ disease are some of the important factors that are fueling the Graves Disease Market.

Graves Disease Pipeline Market Barriers

However, high cost of the treatment, complications associated with the treatment and other factors are creating obstacles in the Graves Disease Market growth.

Scope of Graves Disease Pipeline Drug Insight

Coverage: Global
Key Graves Disease Companies: TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others
Key Graves Disease Therapies: Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others
Graves Disease Therapeutic Assessment: Graves Disease current marketed and Graves Disease emerging therapies
Graves Disease Market Dynamics: Graves Disease market drivers and Graves Disease market barriers

Request for Sample PDF Report for Graves Disease Pipeline Assessment and clinical trials

Table of Contents

1. Graves Disease Report Introduction

2. Graves Disease Executive Summary

3. Graves Disease Overview

4. Graves Disease- Analytical Perspective In-depth Commercial Assessment

5. Graves Disease Pipeline Therapeutics

6. Graves Disease Late Stage Products (Phase II/III)

7. Graves Disease Mid Stage Products (Phase II)

8. Graves Disease Early Stage Products (Phase I)

9. Graves Disease Preclinical Stage Products

10. Graves Disease Therapeutics Assessment

11. Graves Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Graves Disease Key Companies

14. Graves Disease Key Products

15. Graves Disease Unmet Needs

16 . Graves Disease Market Drivers and Barriers

17. Graves Disease Future Perspectives and Conclusion

18. Graves Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graves Disease Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, Hoffmann-La Roche

How Long Does It Take to Become a Mexican Citizen?

Get Mexican citizenship in as little as 3 weeks. Learn how timelines vary, what causes delays, and how to avoid consulate rejections or legal mistakes.

Mexican citizenship timelines vary. Some applicants finish in 3 weeks, others wait months. If you’re reclaiming nationality through a parent, it’s faster. Delays happen due to document issues, rejections, or consulate missteps. Here’s what really affects your wait, and how to avoid mistakes.

How Long It Takes Based on Your Situation:

U.S.-born children of Mexican citizens: 2 to 6 weeks. If documents are clean and names match, the process is quick and can often be done without consulate visits.
Adults reclaiming citizenship through Mexican parents: 1 to 3 months. The timeline depends on document accuracy and whether your parent’s information needs correction.
People rejected or turned away by the consulate: 3 to 6 months. Fixing previous errors and refiling properly with legal support adds time, but success is still possible.
Parents applying for their U.S.-born kids: 4 to 8 weeks. Delays usually occur when one parent’s name or status doesn’t align across documents.
Individuals needing document corrections to qualify: 3 months to over a year. The more complex the correction (e.g., late registration, missing records), the longer the timeline.
Married to a Mexican citizen: 2+ years. Requires 2 years of residency in Mexico, followed by 6 to 12 months of paperwork, tests, and approvals to complete naturalization.

We’ve helped thousands of Mexican Americans reclaim their legal identity without setting foot in a consulate. Our licensed binational legal team specializes in navigating bureaucracy, correcting mismatched names, and avoiding the rejections many families face when they try to do it alone.

Want the full breakdown? Below, we’ll walk through the real timelines, hidden roadblocks, and how to avoid delays, so you can finally claim the citizenship you’re entitled to.

Quick Summary by Applicant Type

U.S.-Born Children of Mexican Citizens

This is often the fastest track. If both your and your Mexican parent’s documents are ready and match, the process can take as little as 2 to 6 weeks. Some of our clients have received their documentation in under a month, without stepping foot in a consulate. Delays usually happen when documents have name mismatches or missing apostilles.

Adults Reclaiming Citizenship Through Mexican Parents

If you’re an adult who was never registered but has at least one Mexican parent, expect 1 to 3 months. This timeline depends on whether your parent’s documents are valid, whether there were any name or marital issues at the time of your birth, and whether you’re applying through an experienced legal team or doing it alone.

Media Contact
Company Name: DNExpress
Contact Person: Aristeo
Email: Send Email
Country: United States
Website: www.dnexpress.org

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: How Long Does It Take to Become a Mexican Citizen?

Latin Food Fest NYC Returns as the Culinary Flagship of Hispanic Heritage Month – This Time, It’s Food First. Always

Latin Food Fest NYC returns Sept 13–14 as the official culinary kickoff to Hispanic Heritage Month. Featuring 70+ POC-owned food vendors, five immersive zones, art, contests, and live performances, the fest is hosted by Panda and Jessica Torres. Rooted in the Raíces Radiantes flag, this isn’t just a party—it’s a movement. Taste the future of Latin culture. Tickets + info: www.TheLatinFoodFest.com

NEW YORK, NY – August 14, 2025 – Hispanic Heritage Month is around the corner — and Latin Food Fest NYC is already setting the table. The original Latin food and music festival, now in its second year, returns to Brooklyn’s Industry City on September 13–14 with 5 explosive zones, 70+ POC-owned vendors, 14 live performances, and one clear message: the future of Latin culture runs through our kitchens.

This isn’t your cousin’s cultural fest.

It’s the culinary flagship of Hispanic Heritage Month, where food is not the side act — it’s the revolution.

Latin Food Fest NYC leads with flavor and founders. These are the chefs, street food legends, and upstart hustlers who feed the city every day — from empanadas and tamales to vegan mole tacos, Puerto Rican sancocho, Dominican pastelón, Peruvian ceviche, and smoked ribs with guava glaze. No filler. No fusion. All fire.

Five zones, five vibes:

La Calle (grill smoke, graffiti, DJs, food trucks)
El Patio (chancla throwing, empanada contests, Bad Bunny lookalikes)
The Dining Hall (chef tastings, Abuela’s Living Room)
The Music Hall (main stage, greenery wall, drinks, perreo)
The Museum (Raíces Radiantes flag, art, VIP lounge, telenovela drama)

Panda (@pandaiscooking) returns to host and taste his way through the chaos. Jessica Torres (@xojessicatorres) joins as official brand ambassador. And dozens of micro-creators will flood TikTok and IG with on-the-ground sabor.

This year’s heartbeat? Raíces Radiantes. A visual flag created for the fest — not to represent one country, but the whole damn continent. One flag. All of Latin America.

Press & creators are invited.

Credentials: press@maschospitalitygroup.com

Tickets & info: www.TheLatinFoodFest.com

LATIN FOOD FEST NYC 2025

September 13–14 | Industry City, Brooklyn | 12–7PM

The Original Latin Food & Music Festival. Often Imitated. Never Duplicated.

Media Contact
Company Name: Latin Food Fest
Contact Person: Marcos Halma
Email: Send Email
Phone: 6467043335
Address:88 Morningside Ave 4E
City: New York
State: NY
Country: United States
Website: https://www.thelatinfoodfest.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Latin Food Fest NYC Returns as the Culinary Flagship of Hispanic Heritage Month – This Time, It’s Food First. Always

Thrombotic Thrombocytopenic Purpura Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc

DelveInsight’s “Thrombotic Thrombocytopenic Purpura Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Thrombotic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the Thrombotic Thrombocytopenic Purpura market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Thrombotic Thrombocytopenic Purpura market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thrombotic Thrombocytopenic Purpura Market Forecast

Some of the key facts of the Thrombotic Thrombocytopenic Purpura Market Report:

The Thrombotic Thrombocytopenic Purpura market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In August 2024, The European Commission (EC) has granted Takeda approval to market ADZYNMA (recombinant ADAMTS13), making it the first and only enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP) in the European Union (EU).
According to Borborema et al. (2020), every 26 years, a family with cTTP has been found by the Oklahoma TTP-HUS registry, which represents a population base of 2 million people. According to the experts, there are 1.5 patients with cTTP for every million people
According to a study by Dorland et al. (2019), cases of cTTP were found in the age ranges of 0–10 years, 10–20 years, 20–30 years, 40–50 years, >50–60 years, 60–70 years, and 70–80 years in 15.8%, 16.6%, 23.3%, 19.1%, 14.1%, 5%, 4.16%, and 1.6%, respectively
According to Borborema et al. (2020), every 26 years, a family with cTTP has been found by the Oklahoma TTP-HUS registry, which represents a population base of 2 million people. According to the experts, there are 1.5 patients with cTTP for every million people
Key Thrombotic Thrombocytopenic Purpura Companies: Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc., Biopharma Plasma, Beijing InnoCare Pharma, Shionogi, Takeda, and others
Key Thrombotic Thrombocytopenic Purpura Therapies: Inclacumab, Caplacizumab, Rituximab, ARC 1779, Eltrombopag, Intravenous immunoglobulin (IVIG), Orelabrutinib, Lusutrombopag, TAK-079, and others
The Thrombotic Thrombocytopenic Purpura epidemiology based on gender analyzed that it was seen that women represented 61.3% of Medicare FFS beneficiaries, 67.5% of Medicare advantage plan members, 66.3% of commercial plan members, and 79.1% of managed Medicaid members
The Thrombotic Thrombocytopenic Purpura market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thrombotic Thrombocytopenic Purpura pipeline products will significantly revolutionize the Thrombotic Thrombocytopenic Purpura market dynamics.

Thrombotic Thrombocytopenic Purpura Overview

Thrombotic Thrombocytopenic Purpura (TTP) is a rare and potentially life-threatening blood disorder characterized by the formation of small blood clots (thrombi) throughout the body. These clots can block blood flow to vital organs, leading to organ damage. TTP is associated with a low platelet count (thrombocytopenia), which results in easy bruising, purplish spots on the skin (purpura), and increased bleeding risk. It can also cause symptoms such as fatigue, confusion, kidney dysfunction, and fever. The condition is often triggered by an autoimmune response that inhibits the activity of an enzyme called ADAMTS13, leading to the formation of clots. Treatment typically involves plasma exchange therapy, corticosteroids, and immunosuppressive drugs.

Get a Free sample for the Thrombotic Thrombocytopenic Purpura Market Report:

https://www.delveinsight.com/report-store/thrombotic-thrombocytopenic-purpura-market

Thrombotic Thrombocytopenic Purpura Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Thrombotic Thrombocytopenic Purpura Epidemiology Segmentation:

The Thrombotic Thrombocytopenic Purpura market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Thrombotic Thrombocytopenic Purpura
Prevalent Cases of Thrombotic Thrombocytopenic Purpura by severity
Gender-specific Prevalence of Thrombotic Thrombocytopenic Purpura
Diagnosed Cases of Episodic and Chronic Thrombotic Thrombocytopenic Purpura

Download the report to understand which factors are driving Thrombotic Thrombocytopenic Purpura epidemiology trends @ Thrombotic Thrombocytopenic Purpura Epidemiology Forecast

Thrombotic Thrombocytopenic Purpura Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thrombotic Thrombocytopenic Purpura market or expected to get launched during the study period. The analysis covers Thrombotic Thrombocytopenic Purpura market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Thrombotic Thrombocytopenic Purpura Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Thrombotic Thrombocytopenic Purpura Therapies and Key Companies

Inclacumab: Global Blood Therapeutics
Caplacizumab: Sanofi
Rituximab: Carelon Research
ARC 1779: Archemix Corp.
Eltrombopag: Eisai Inc.
Intravenous immunoglobulin (IVIG): Biopharma Plasma
Orelabrutinib: Beijing InnoCare Pharma
Lusutrombopag: Shionogi
TAK-079: Takeda

Discover more about therapies set to grab major Thrombotic Thrombocytopenic Purpura market share @ Thrombotic Thrombocytopenic Purpura Treatment Market

Thrombotic Thrombocytopenic Purpura Market Drivers

The use of off-label branded and generic prescription medications targeted at individual symptoms of Netherton Syndrome, including antiepileptics, antipsychotics, antidepressants and benzodiazepines.
Several academic institutions and pharmaceutical companies are currently conducting clinical trials for the treatment of various symptoms of Netherton Syndrome.

Thrombotic Thrombocytopenic Purpura Market Barriers

New therapeutic options are needed to address the unmet need for effective and curative therapies for Netherton Syndrome. This has created an opportunity for key players to develop novel therapies targeted towards this indication

Scope of the Thrombotic Thrombocytopenic Purpura Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Thrombotic Thrombocytopenic Purpura Companies: Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc., Biopharma Plasma, Beijing InnoCare Pharma, Shionogi, Takeda, and others
Key Thrombotic Thrombocytopenic Purpura Therapies: Inclacumab, Caplacizumab, Rituximab, ARC 1779, Eltrombopag, Intravenous immunoglobulin (IVIG), Orelabrutinib, Lusutrombopag, TAK-079, and others
Thrombotic Thrombocytopenic Purpura Therapeutic Assessment: Thrombotic Thrombocytopenic Purpura current marketed and Thrombotic Thrombocytopenic Purpura emerging therapies
Thrombotic Thrombocytopenic Purpura Market Dynamics: Thrombotic Thrombocytopenic Purpura market drivers and Thrombotic Thrombocytopenic Purpura market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Thrombotic Thrombocytopenic Purpura Unmet Needs, KOL’s views, Analyst’s views, Thrombotic Thrombocytopenic Purpura Market Access and Reimbursement

To know more about Thrombotic Thrombocytopenic Purpura companies working in the treatment market, visit @ Thrombotic Thrombocytopenic Purpura Clinical Trials and Therapeutic Assessment

Table of Contents

1. Thrombotic Thrombocytopenic Purpura Market Report Introduction

2. Executive Summary for Thrombotic Thrombocytopenic Purpura

3. SWOT analysis of Thrombotic Thrombocytopenic Purpura

4. Thrombotic Thrombocytopenic Purpura Patient Share (%) Overview at a Glance

5. Thrombotic Thrombocytopenic Purpura Market Overview at a Glance

6. Thrombotic Thrombocytopenic Purpura Disease Background and Overview

7. Thrombotic Thrombocytopenic Purpura Epidemiology and Patient Population

8. Country-Specific Patient Population of Thrombotic Thrombocytopenic Purpura

9. Thrombotic Thrombocytopenic Purpura Current Treatment and Medical Practices

10. Thrombotic Thrombocytopenic Purpura Unmet Needs

11. Thrombotic Thrombocytopenic Purpura Emerging Therapies

12. Thrombotic Thrombocytopenic Purpura Market Outlook

13. Country-Wise Thrombotic Thrombocytopenic Purpura Market Analysis (2020–2034)

14. Thrombotic Thrombocytopenic Purpura Market Access and Reimbursement of Therapies

15. Thrombotic Thrombocytopenic Purpura Market Drivers

16. Thrombotic Thrombocytopenic Purpura Market Barriers

17. Thrombotic Thrombocytopenic Purpura Appendix

18. Thrombotic Thrombocytopenic Purpura Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thrombotic Thrombocytopenic Purpura Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc

Atherosclerotic Cardiovascular Disease Market Expected to Gain Momentum Through 2034, According to DelveInsight | Amgen, Novo Nordisk A/S, Ionis Pharma, NewAmsterdam Pharma, ResverlogixCorp, Novartis

The Key Atherosclerotic Cardiovascular Disease Companies in the market include – Novartis, Regeneron Pharmaceuticals, Sanofi, Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, LIB Therapeutics, Merck Sharp & Dohme LLC, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others.

DelveInsight’s “Atherosclerotic Cardiovascular Disease (ASCVD) Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Atherosclerotic Cardiovascular Disease, historical and forecasted epidemiology as well as the Atherosclerotic Cardiovascular Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Atherosclerotic Cardiovascular Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Atherosclerotic Cardiovascular Disease Market Forecast

Some of the key facts of the Atherosclerotic Cardiovascular Disease Market Report:

The Atherosclerotic Cardiovascular Disease market size was valued approximately USD 23,370 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In December 2024, NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a late-stage biopharmaceutical company focused on developing oral, non-statin treatments for patients at risk of cardiovascular disease (CVD) with elevated LDL cholesterol, announced promising topline results from its Phase 3 BROADWAY clinical trial (NCT05142722). The trial assessed obicetrapib in adult patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL cholesterol levels remain inadequately controlled despite being on the maximum tolerated lipid-lowering therapy.
In 2023, the United States held the largest share of the ASCVD market, accounting for approximately 52% of the total market size across the 7MM. This was notably higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Within the EU countries, Germany recorded the largest market size for ASCVD, reaching approximately USD 2,275 million in 2023. In contrast, the UK had the smallest market size, at around USD 1,325 million during the same year.
In 2023, Japan’s market size for ASCVD was approximately USD 3,058 million.
According to DelveInsight’s analysis, the total diagnosed prevalent cases of Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM were approximately 55.7 million in 2023.
In 2023, the United States recorded the highest number of diagnosed prevalent cases of ASCVD, totaling 26 million, with projections indicating future growth.
In 2023, Germany reported the highest number of diagnosed prevalent ASCVD cases among European countries, with approximately 5 million cases, followed by France at around 4 million. In contrast, Spain had the lowest diagnosed prevalence, with 3 million cases.
In 2023, Japan recorded approximately 8 million diagnosed prevalent cases of ASCVD, representing around 15% of the total cases in the 7MM.
Analysis reveals that in 2023, across the EU4 and the UK, males were more impacted by ASCVD than females, with around 12 million cases in males compared to 8 million in females.
The diagnosed prevalent population of ASCVD in Japan was categorized into three age groups: 18–44 years, 45–64 years, and 65+ years. In 2023, the 45–64-year age group had the highest number of cases, approximately 5,480 thousand, followed by the 18–44-year group with around 1,645 thousand cases, and the 65+ year group with roughly 1,100 thousand cases.
Key Atherosclerotic Cardiovascular Disease Companies: Novartis, Regeneron Pharmaceuticals, Sanofi, Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, LIB Therapeutics, Merck Sharp & Dohme LLC, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
Key Atherosclerotic Cardiovascular Disease Therapies: LEQVIO (inclisiran), PRALUENT (alirocumab), Olpasiran, Ziltivekimab, Olezarsen, Obicetrapib(TA-8995), Apabetalone, LIB003 (Lerodalcibep), CSL112: CSL Behring, TQJ230 (pelacarsen), MK-0616, Inclisiran, Ertugliflozin, Tetrahydrobiopterin, MEDI6570, GFH312, and others
The Atherosclerotic Cardiovascular Disease epidemiology based on gender analyzed that men bear a greater burden than women regarding Atherosclerotic Cardiovascular Disease (ASCVD) in the 7MM
The Atherosclerotic Cardiovascular Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atherosclerotic Cardiovascular Disease pipeline products will significantly revolutionize the Atherosclerotic Cardiovascular Disease market dynamics.

Atherosclerotic Cardiovascular Disease Overview

Atherosclerotic Cardiovascular Disease (ASCVD) is a condition where the arteries become narrowed and hardened due to the buildup of plaque, which consists of fatty deposits, cholesterol, and other substances. This process, known as atherosclerosis, can restrict blood flow to the heart, brain, and other parts of the body, increasing the risk of heart attacks, strokes, and peripheral artery disease. Common risk factors for ASCVD include high blood pressure, high cholesterol, smoking, diabetes, and a sedentary lifestyle. Management often involves lifestyle changes, medications to control risk factors, and, in some cases, surgical interventions to improve blood flow.

Get a Free sample for the Atherosclerotic Cardiovascular Disease Market Report:

https://www.delveinsight.com/report-store/atherosclerotic-cardiovascular-disease-ascvd-market

Atherosclerotic Cardiovascular Disease Epidemiology

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation:

The Atherosclerotic Cardiovascular Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Atherosclerotic Cardiovascular Disease
Prevalent Cases of Atherosclerotic Cardiovascular Disease by severity
Gender-specific Prevalence of Atherosclerotic Cardiovascular Disease
Diagnosed Cases of Episodic and Chronic Atherosclerotic Cardiovascular Disease

Download the report to understand which factors are driving Atherosclerotic Cardiovascular Disease epidemiology trends @ Atherosclerotic Cardiovascular Disease Epidemiology Forecast

Atherosclerotic Cardiovascular Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Atherosclerotic Cardiovascular Disease market or expected to get launched during the study period. The analysis covers Atherosclerotic Cardiovascular Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Atherosclerotic Cardiovascular Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Atherosclerotic Cardiovascular Disease Therapies and Key Companies

LEQVIO (inclisiran): Novartis Pharmaceuticals Corporation
PRALUENT (alirocumab): Regeneron Pharmaceuticals/Sanofi
Olpasiran: Amgen
Ziltivekimab: Novo Nordisk A/S
Olezarsen: Ionis Pharmaceuticals
Obicetrapib(TA-8995): NewAmsterdam Pharma
Apabetalone: ResverlogixCorp
LIB003 (Lerodalcibep): LIB Therapeutics
CSL112: CSL Behring
TQJ230 (pelacarsen): Novartis Pharmaceuticals
MK-0616: Merck Sharp & Dohme LLC
Inclisiran: Novartis Pharmaceuticals
Ertugliflozin: Merck Sharp & Dohme LLC
Tetrahydrobiopterin: BioMarin Pharmaceutical
MEDI6570: AstraZeneca
GFH312: Zhejiang Genfleet Therapeutics Co., Ltd.

Discover more about therapies set to grab major Atherosclerotic Cardiovascular Disease market share @ Atherosclerotic Cardiovascular Disease Treatment Market

Atherosclerotic Cardiovascular Disease Market Strengths

Robust pipeline of drugs targeting a variety of different and more effective pathogenic mechanisms in Atherosclerotic Cardiovascular Disease (ASCVD).

Atherosclerotic Cardiovascular Disease Market Opportunities

The lack of FDA-approved treatments for lowering Lp(a)presents an exciting opportunity for focused research on developing precise therapies in the realm of ASCVD

Scope of the Atherosclerotic Cardiovascular Disease Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Atherosclerotic Cardiovascular Disease Companies: Novartis, Regeneron Pharmaceuticals, Sanofi, Amgen, Novo Nordisk A/S, Ionis Pharmaceuticals, NewAmsterdam Pharma, ResverlogixCorp, LIB Therapeutics, Merck Sharp & Dohme LLC, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
Key Atherosclerotic Cardiovascular Disease Therapies: LEQVIO (inclisiran), PRALUENT (alirocumab), Olpasiran, Ziltivekimab, Olezarsen, Obicetrapib(TA-8995), Apabetalone, LIB003 (Lerodalcibep), CSL112: CSL Behring, TQJ230 (pelacarsen), MK-0616, Inclisiran, Ertugliflozin, Tetrahydrobiopterin, MEDI6570, GFH312, and others
Atherosclerotic Cardiovascular Disease Therapeutic Assessment: Atherosclerotic Cardiovascular Disease current marketed and Atherosclerotic Cardiovascular Disease emerging therapies
Atherosclerotic Cardiovascular Disease Market Dynamics: Atherosclerotic Cardiovascular Disease market drivers and Atherosclerotic Cardiovascular Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Atherosclerotic Cardiovascular Disease Unmet Needs, KOL’s views, Analyst’s views, Atherosclerotic Cardiovascular Disease Market Access and Reimbursement

To know more about Atherosclerotic Cardiovascular Disease companies working in the treatment market, visit @ Atherosclerotic Cardiovascular Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Atherosclerotic Cardiovascular Disease Market Report Introduction

2. Executive Summary for Atherosclerotic Cardiovascular Disease

3. SWOT analysis of Atherosclerotic Cardiovascular Disease

4. Atherosclerotic Cardiovascular Disease Patient Share (%) Overview at a Glance

5. Atherosclerotic Cardiovascular Disease Market Overview at a Glance

6. Atherosclerotic Cardiovascular Disease Disease Background and Overview

7. Atherosclerotic Cardiovascular Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Atherosclerotic Cardiovascular Disease

9. Atherosclerotic Cardiovascular Disease Current Treatment and Medical Practices

10. Atherosclerotic Cardiovascular Disease Unmet Needs

11. Atherosclerotic Cardiovascular Disease Emerging Therapies

12. Atherosclerotic Cardiovascular Disease Market Outlook

13. Country-Wise Atherosclerotic Cardiovascular Disease Market Analysis (2020–2034)

14. Atherosclerotic Cardiovascular Disease Market Access and Reimbursement of Therapies

15. Atherosclerotic Cardiovascular Disease Market Drivers

16. Atherosclerotic Cardiovascular Disease Market Barriers

17. Atherosclerotic Cardiovascular Disease Appendix

18. Atherosclerotic Cardiovascular Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atherosclerotic Cardiovascular Disease Market Expected to Gain Momentum Through 2034, According to DelveInsight | Amgen, Novo Nordisk A/S, Ionis Pharma, NewAmsterdam Pharma, ResverlogixCorp, Novartis